Pfizer (XSWX:PFE) Payments of Debt: CHF-3,005 Mil (TTM As of Mar. 2026)


XSWX:PFE Pfizer Inc XSWX:PFE
59 GF Score
Price CHF19.58
GF Value CHF21.37
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Pfizer Payments of Debt?

Pfizer XSWX:PFE -2.00% 59 Payments of Debt is CHF-3,005 Mil as of Mar. 2026. GuruFocus rates XSWX:PFE with a GF Score™ of 59/100 and a GF Value™ of CHF21.37 (Fairly Valued). The stock has 5 warning signs investors should review.

Pfizer's Payments of Debt for the three months ended in Mar. 2026 was CHF-100 Mil.

Pfizer's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-3,005 Mil.

Pfizer Payments of Debt Related Terms

Pfizer Payments of Debt Historical Data

* Premium members only.

The historical data trend for Pfizer's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Payments of Debt Chart

Pfizer Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,934.10 -6,900.36 -2,224.27 -14,324.45 -7,771.37

Pfizer Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,150.68 -594.45 4.78 -2,315.79 -99.99
XSWX:PFE
59GF Score
Pfizer Inc XSWX:PFE
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pfizer Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-3,005 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of CHF-3,005 Mil mean?
Pfizer (XSWX:PFE) has a Payments of Debt of CHF-3,005 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Pfizer and its competitors.
Is Pfizer's Payments of Debt too high?
Pfizer's current Payments of Debt is CHF-3,005 Mil. Overall, Pfizer has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Payments of Debt compare to GILD and BMY?
Pfizer's Payments of Debt of CHF-3,005 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Drug Manufacturers company?
A good Payments of Debt depends on the Drug Manufacturers industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Pfizer and its competitors. Pfizer's current Payments of Debt is CHF-3,005 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (XSWX:PFE) is currently considered Fairly Valued. The stock's GF Value™ is CHF21.37, compared to a current price of CHF19.58 — trading 8.4% below its estimated fair value. The current Payments of Debt is CHF-3,005 Mil. Pfizer's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Pfizer (XSWX:PFE), the current Payments of Debt is CHF-3,005 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pfizer (XSWX:PFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be undervalued. The current stock price of CHF19.58 is trading 8.4% below its estimated GF Value™ of CHF21.37. GuruFocus considers Pfizer to be Fairly Valued.

Key valuation signals for XSWX:PFE:

  • Payments of Debt: CHF-3,005 Mil
  • GF Value™: CHF21.37 vs. price of CHF19.58 (8.4% below fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the XSWX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
59GF Score

Get the complete analysis for XSWX:PFE

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF19.58
Price
CHF21.37
GF Value